Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.94Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: -4.73%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, significant product upgrades, and successful cost reductions, indicating a positive trajectory for Guardant Health. However, litigation expenses and challenges with NCCN guidelines presented some obstacles. Overall, the positive developments outweighed the lowlights.Company Guidance
During the Guardant Health Q4 2024 earnings call, management provided guidance indicating a strong year ahead. The company expects total revenue for 2025 to range between $850 million and $860 million, representing a 15% to 16% growth compared to 2024. This guidance excludes a $22 million non-recurring out-of-period revenue upside in 2024, implying an adjusted growth of 19% to 20%. Oncology revenue is forecasted to grow approximately 15% year-over-year, excluding the non-recurring upside, with clinical volume growth expected at around 25%. The biopharma and data segment is anticipated to see low double-digit growth, while screening revenue from Shield is projected between $25 million and $30 million, driven by 45,000 to 50,000 tests. The company also plans for full-year non-GAAP gross margins of 62% to 63% and aims to reduce free cash flow burn to between $225 million and $235 million, with a focus on maintaining their screening cash burn at approximately $200 million.Record Revenue Growth
Q4 2024 revenue grew 30% year-over-year to $202 million, bringing total full year revenue to $739 million, an increase of 31% year-over-year.
Clinical Revenue and Volume Surge
Clinical revenue grew 34% year-over-year, with total oncology clinical volumes increasing 24% in Q4 and 20% for the full year.
Major Product Upgrades
Guardant360 Test upgraded to the Smart Liquid Biopsy platform, expanding genomic markers and improving detection sensitivity by a factor of 10.
Significant ASP Improvement
Guardant360 ASP increased from $2,750 to $3,000, achieving a target four years ahead of schedule due to reimbursement wins.
Shield FDA Approval and Medicare Coverage
Shield became the first FDA-approved and Medicare-covered blood test for CRC screening, with a Medicare price of $920 and potential increase to $1,495.
Cost Reductions and Financial Health
Reveal achieved more than 50% reduction in COGS, and the company ended the year with approximately $944 million in cash, expecting cash flow break-even by 2028.
---
GH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $47.40 | $42.87 | -9.56% |
| Nov 06, 2024 | $25.29 | $28.59 | +13.05% |
| Aug 07, 2024 | $33.96 | $30.27 | -10.87% |
| May 09, 2024 | $19.44 | $22.37 | +15.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Guardant Health (GH) report earnings?
Guardant Health (GH) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Guardant Health (GH) earnings time?
Guardant Health (GH) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GH EPS forecast?
GH EPS forecast for the fiscal quarter 2025 (Q1) is -0.75.
---